Century Therapeutics (IPSC) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Century Therapeutics (IPSC) has outperformed Surrozen (SRZN) over the past year, gaining 150.0% versus a gain of 99.2%. Over five years, SRZN leads with a -70.5% price change compared with -92.4% for IPSC. Surrozen is the larger company by market cap ($328.7 million vs $264.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPSC | SRZN |
|---|---|---|
| Share price | $1.46 | $27.97 |
| Market cap | $264.37M | $328.75M |
| 1-day change | +14.06% | +11.23% |
| YTD return | +46.73% | +23.76% |
| 1-year return | +150.00% | +99.22% |
| 5-year return | -92.44% | -70.50% |
| EPS (TTM) | $-0.93 | $-39.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.04 | $37.83 |
| 52-week low | $0.435 | $11.39 |
| Distance from 52-week high | -51.97% | -26.06% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +225.34% | +73.04% |
| Average volume | 649.61K | 483.28K |
| Shares outstanding | 181.08M | 11.75M |
| Employees | 78 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPSC has outperformed SRZN by 50.8 percentage points over the past year.
About Century Therapeutics
IPSC stock →Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
IPSC vs SRZN FAQ
Which is bigger, Century Therapeutics or Surrozen?
Surrozen (SRZN) is larger, with a market capitalization of $328.75M compared with $264.37M for Century Therapeutics (IPSC).
Which stock has performed better over the past year, IPSC or SRZN?
IPSC returned +150.00% over the past 12 months, compared with +99.22% for SRZN (price return, excluding dividends). Past performance does not predict future results.
Are Century Therapeutics and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.